Huabei Pharmaceutical Group To Relocate In Hebei
This article was originally published in PharmAsia News
Executive Summary
Huabei Pharmaceutical Group and its subsidiaries will start shifting to Liangcun Economic and Technical Development Zone from this July. The relocation project, supported by Hebei province, has been allocated a total investment of 2.360 billion yuan ($338 million), of which new fixed assets take up 1.460 billion yuan ($209 million). After the move, Huabei Pharmaceutical's revenue is estimated to reach 3.508 billion yuan (502 million), with new sales and profit to hit 1.777 billion yuan and 500 million yuan respectively. Huabei Pharmaceutical will also focus on consolidating its joint venture with DSM this year. (Click here for more - Chinese Language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.